A genome-wide association study of 2057 European patients with advanced cancer receiving opioid treatment identified PCMTD2 and OPRL1 on chromosome 20 as associated with variations in the regulation of cancer pain intensity [266]. The gene discussed is PCMTD2; the disease is cancer.